The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis

Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphy

“…As 1H-MRS allows direct measurement of the area under the lipid resonance curve, it may also provide a quantitative assessment of fatty infiltration of the liver [28] . Although results from this method correlate well with those obtained by CT and liver biopsy [25,29,30] , 1H-MRS remains a research tool, despite the fact that MRI scanners have 1H-MRS capabilities [31,32] . An additional magnetic resonance-based technique uses gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB) as a contrast agent.…”

“…Reduction of the out-phase signal on T1-weighted images is an accurate predictor of hepatic fat content compared with the histologic assessment [23] . Although many MRI techniques have been developed to improve its performance in the diagnostic spectrum of NAFLD and provide a quantitative assessment of hepatic fatty infiltration [23][24][25] , these methods are limited in their ability to detect coexisting inflammation or fibrosis [24] . Moreover, MRI is costly, time consuming, and motion artifacts, such as from respiration, can affect image quality [26,27] .…”

Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study

“…Hepatic steatosis has been reported in patients with CRC who have been treated by regimens including 5FU/interferon , HAI‐FUDR , 5FU/folinic acid and 5FU/levamisole . However, others have reported that steatosis is no higher in treated patients than in chemotherapy‐naïve cohorts . Recently, Makowiec et al .…”

“…Hepatic steatosis has been reported in patients with CRC who have been treated by regimens including 5FU/interferon (28), HAI-FUDR (29), 5FU/folinic acid (30) and 5FU/levamisole (31). However, others have reported that steatosis is no higher in treated patients than in chemotherapy-naïve cohorts (7,9,16,32,33). Recently, Makowiec et al (34) reported a histologic steatosis rate of 46% in patients who had received 5FU-based, oxaliplatinbased or IRI-based treatment, and a rate of 18% in a similar population which had not undergone chemotherapy.…”

“…This pilot study examines the effectiveness of 1 H MRS, a noninvasive test, for the monitoring of hepatic triglycerides (HTGCs) during chemotherapy. 1 H MRS has been widely used to assess liver lipids and has been found to agree well with histology . MRI techniques for the quantitative assessment of liver fat have advanced rapidly in recent years and compare favorably in accuracy with MRS.…”